CHMP Knocks Back TLC’s Doxorubicin Hybrid

 
• By David Wallace
  
Hybrid
TLC Biopharmaceuticals Has Seen Its Hybrid Doxorubicin Application Rejected • Source: Shutterstock

More from Regulation

More from Policy & Regulation